🇺🇸 FDA
Pipeline program

Recombinant human hyaluronidase + immune globulin intravenous

160602

Phase 2 mab completed

Quick answer

Recombinant human hyaluronidase + immune globulin intravenous for Primary Immunodeficiency Diseases (PID) is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Primary Immunodeficiency Diseases (PID)
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials